Shionogi Of Japan Begins Second-Phase Trials For Anti-Itch Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi said Phase II clinical trials have begun in Japan for its drug to treat itching caused by atopic dermatitis, a condition affecting six million Japanese